DBV TECHNOLOGIES SA-SPON ADR (DBVT)
US23306J1016 - ADR
Overall DBVT gets a fundamental rating of 3 out of 10. We evaluated DBVT against 588 industry peers in the Biotechnology industry. DBVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, DBVT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year DBVT has reported negative net income.
In the past year DBVT has reported a negative cash flow from operations.
In the past 5 years DBVT always reported negative net income.
DBVT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
DBVT has a Return On Assets of -44.15%. This is comparable to the rest of the industry: DBVT outperforms 56.31% of its industry peers.
DBVT's Return On Equity of -58.44% is fine compared to the rest of the industry. DBVT outperforms 63.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.15% | ||
| ROE | -58.44% | ||
| ROIC | N/A |
ROA(3y)-54.89%
ROA(5y)-64.99%
ROE(3y)-75.37%
ROE(5y)-90.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DBVT has a Gross Margin of 83.94%. This is amongst the best in the industry. DBVT outperforms 89.25% of its industry peers.
DBVT's Gross Margin has been stable in the last couple of years.
DBVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.22%
GM growth 5Y-0.62%
2. Health
2.1 Basic Checks
DBVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
DBVT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DBVT has been increased compared to 5 years ago.
Compared to 1 year ago, DBVT has an improved debt to assets ratio.
2.2 Solvency
DBVT has an Altman-Z score of 0.67. This is a bad value and indicates that DBVT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DBVT (0.67) is better than 63.14% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that DBVT is not too dependend on debt financing.
DBVT has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.67 |
ROIC/WACCN/A
WACC7.21%
2.3 Liquidity
A Current Ratio of 5.86 indicates that DBVT has no problem at all paying its short term obligations.
The Current ratio of DBVT (5.86) is better than 61.09% of its industry peers.
DBVT has a Quick Ratio of 5.86. This indicates that DBVT is financially healthy and has no problem in meeting its short term obligations.
DBVT has a Quick ratio of 5.86. This is in the better half of the industry: DBVT outperforms 61.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.86 | ||
| Quick Ratio | 5.86 |
3. Growth
3.1 Past
DBVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.52%, which is quite good.
Looking at the last year, DBVT shows a very negative growth in Revenue. The Revenue has decreased by -15.14% in the last year.
DBVT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -17.36% yearly.
EPS 1Y (TTM)10.52%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q25.67%
Revenue 1Y (TTM)-15.14%
Revenue growth 3Y-30.94%
Revenue growth 5Y-17.36%
Revenue growth Q2Q10.01%
3.2 Future
Based on estimates for the next years, DBVT will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.10% on average per year.
DBVT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 79.35% yearly.
EPS Next Y31.48%
EPS Next 2Y14.89%
EPS Next 3Y17.72%
EPS Next 5Y13.1%
Revenue Next Year-13.45%
Revenue Next 2Y33.44%
Revenue Next 3Y-19.41%
Revenue Next 5Y79.35%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DBVT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBVT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as DBVT's earnings are expected to grow with 17.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.89%
EPS Next 3Y17.72%
5. Dividend
5.1 Amount
No dividends for DBVT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DBV TECHNOLOGIES SA-SPON ADR
NASDAQ:DBVT (5/2/2024, 2:57:42 PM)
0.6805
-0.01 (-1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap130.89M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.15% | ||
| ROE | -58.44% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.86 | ||
| Quick Ratio | 5.86 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)10.52%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y31.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-15.14%
Revenue growth 3Y-30.94%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y